Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02007005

Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer

Dose-Escalation-Study With abnobaVISCUM® Fraxini 2 (AVF2) as Intravesical Instillation in Patients With Superficial Bladder Cancer According to ICH/GCP (International Conference on Harmonisation/Good Clinical Practice) - Guidelines: a Phase Ib/IIa Study

Sponsor: Abnoba Gmbh

Conditions Superficial Bladder Cancer

Interventions abnobaVISCUM Fraxini

Updated 5 times since 2017 Last updated: May 5, 2015 Started: Jan 31, 2004 Primary completion: Feb 29, 2012 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02007005, this PHASE1/PHASE2 trial focuses on Superficial Bladder Cancer and remains completed. Sponsored by Abnoba Gmbh, it has been updated 5 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abnoba Gmbh

Data source: Abnoba Gmbh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Essen, Germany
• Giza, Egypt